English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
Key Takeaways
- AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they’re continuing to increase investment in the country
- Growing tensions between China and the US are making many companies nervous about their operations in China, and AstraZeneca is no exception
- They’ve reportedly drawn up plans to split their Chinese operations and list in Hong Kong or Shanghai, but the company has shrugged this off as a “rumor”.
AstraZeneca is the UK’s largest publicly traded company, but in a sector that’s known for big bets, big wins and big losses, there’s always plenty of room for growth. And that’s especially the case for Astrazeneca, who, despite a market cap of over $170 billion, only just cracks the global top ten when it comes to pharmaceutical company revenue.
But areas for growth are becoming harder to come by. Growth in the US, the UK and Europe is low, and pharmaceutical companies face increased pressure from lawsuits and regulation.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
